Review of auranofin, an oral chrysotherapeutic agent

J. C. Delafuente, Thomas Osborn

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

The chemistry, pharmacology, pharmacokinetics, clinical use and efficacy, adverse effects, and dosage of auranofin, an oral chrysotherapeutic agent used in treatment of rheumatoid arthritis, are reviewed. Auranofin is lipid-soluble and is monomeric in solution. It has a modulatory effect on both the humoral and cellular immune systems. Auranofin may be a condition-dependent immunoregulating agent rather than an immunosuppressive agent. It inhibits (1) monocyte-mediated antibody-dependent cellular toxicity, (2) release of enzymes from polymorphonuclear leukocytes that may contribute to the pathogenesis of rheumatoid arthritis, and (3) neutrophil activity. In patients with rheumatoid arthritis, 15-33% of an oral dose of auranofin 6 mg is absorbed. Peak plasma gold concentrations are achieved in one to two hours. Gold is highly protein bound. Elimination occurs through the feces and urine; 73-100% of auranofin gold is excreted. Plasma half-life is three weeks. Patients receiving auranofin 3 mg twice daily for rheumatoid arthritis reported improvement after five weeks of therapy; improvement has also been reported with lower doses. Diarrhea, rashes, and pruritus were the most common adverse effects. Auranofin is safe and effective for short- and long-term treatment of patients with rheumatoid arthritis. Its relative safety and potency compared with injectable gold salts and other drugs need further study.

Original languageEnglish (US)
Pages (from-to)121-127
Number of pages7
JournalClinical Pharmacy
Volume3
Issue number2
StatePublished - Jan 1 1984
Externally publishedYes

Fingerprint

Auranofin
Rheumatoid Arthritis
Gold
Neutrophils
Pruritus
Immunosuppressive Agents
Exanthema
Feces
Half-Life
Monocytes
Diarrhea
Immune System
Therapeutics
Pharmacokinetics
Salts
Urine
Pharmacology
Lipids
Safety
Injections

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Review of auranofin, an oral chrysotherapeutic agent. / Delafuente, J. C.; Osborn, Thomas.

In: Clinical Pharmacy, Vol. 3, No. 2, 01.01.1984, p. 121-127.

Research output: Contribution to journalReview article

Delafuente, JC & Osborn, T 1984, 'Review of auranofin, an oral chrysotherapeutic agent', Clinical Pharmacy, vol. 3, no. 2, pp. 121-127.
Delafuente, J. C. ; Osborn, Thomas. / Review of auranofin, an oral chrysotherapeutic agent. In: Clinical Pharmacy. 1984 ; Vol. 3, No. 2. pp. 121-127.
@article{01682a620ee9462f9ec3ecc465355587,
title = "Review of auranofin, an oral chrysotherapeutic agent",
abstract = "The chemistry, pharmacology, pharmacokinetics, clinical use and efficacy, adverse effects, and dosage of auranofin, an oral chrysotherapeutic agent used in treatment of rheumatoid arthritis, are reviewed. Auranofin is lipid-soluble and is monomeric in solution. It has a modulatory effect on both the humoral and cellular immune systems. Auranofin may be a condition-dependent immunoregulating agent rather than an immunosuppressive agent. It inhibits (1) monocyte-mediated antibody-dependent cellular toxicity, (2) release of enzymes from polymorphonuclear leukocytes that may contribute to the pathogenesis of rheumatoid arthritis, and (3) neutrophil activity. In patients with rheumatoid arthritis, 15-33{\%} of an oral dose of auranofin 6 mg is absorbed. Peak plasma gold concentrations are achieved in one to two hours. Gold is highly protein bound. Elimination occurs through the feces and urine; 73-100{\%} of auranofin gold is excreted. Plasma half-life is three weeks. Patients receiving auranofin 3 mg twice daily for rheumatoid arthritis reported improvement after five weeks of therapy; improvement has also been reported with lower doses. Diarrhea, rashes, and pruritus were the most common adverse effects. Auranofin is safe and effective for short- and long-term treatment of patients with rheumatoid arthritis. Its relative safety and potency compared with injectable gold salts and other drugs need further study.",
author = "Delafuente, {J. C.} and Thomas Osborn",
year = "1984",
month = "1",
day = "1",
language = "English (US)",
volume = "3",
pages = "121--127",
journal = "Clinical Pharmacy",
issn = "0278-2677",
publisher = "American Society of Hospital Pharmacists",
number = "2",

}

TY - JOUR

T1 - Review of auranofin, an oral chrysotherapeutic agent

AU - Delafuente, J. C.

AU - Osborn, Thomas

PY - 1984/1/1

Y1 - 1984/1/1

N2 - The chemistry, pharmacology, pharmacokinetics, clinical use and efficacy, adverse effects, and dosage of auranofin, an oral chrysotherapeutic agent used in treatment of rheumatoid arthritis, are reviewed. Auranofin is lipid-soluble and is monomeric in solution. It has a modulatory effect on both the humoral and cellular immune systems. Auranofin may be a condition-dependent immunoregulating agent rather than an immunosuppressive agent. It inhibits (1) monocyte-mediated antibody-dependent cellular toxicity, (2) release of enzymes from polymorphonuclear leukocytes that may contribute to the pathogenesis of rheumatoid arthritis, and (3) neutrophil activity. In patients with rheumatoid arthritis, 15-33% of an oral dose of auranofin 6 mg is absorbed. Peak plasma gold concentrations are achieved in one to two hours. Gold is highly protein bound. Elimination occurs through the feces and urine; 73-100% of auranofin gold is excreted. Plasma half-life is three weeks. Patients receiving auranofin 3 mg twice daily for rheumatoid arthritis reported improvement after five weeks of therapy; improvement has also been reported with lower doses. Diarrhea, rashes, and pruritus were the most common adverse effects. Auranofin is safe and effective for short- and long-term treatment of patients with rheumatoid arthritis. Its relative safety and potency compared with injectable gold salts and other drugs need further study.

AB - The chemistry, pharmacology, pharmacokinetics, clinical use and efficacy, adverse effects, and dosage of auranofin, an oral chrysotherapeutic agent used in treatment of rheumatoid arthritis, are reviewed. Auranofin is lipid-soluble and is monomeric in solution. It has a modulatory effect on both the humoral and cellular immune systems. Auranofin may be a condition-dependent immunoregulating agent rather than an immunosuppressive agent. It inhibits (1) monocyte-mediated antibody-dependent cellular toxicity, (2) release of enzymes from polymorphonuclear leukocytes that may contribute to the pathogenesis of rheumatoid arthritis, and (3) neutrophil activity. In patients with rheumatoid arthritis, 15-33% of an oral dose of auranofin 6 mg is absorbed. Peak plasma gold concentrations are achieved in one to two hours. Gold is highly protein bound. Elimination occurs through the feces and urine; 73-100% of auranofin gold is excreted. Plasma half-life is three weeks. Patients receiving auranofin 3 mg twice daily for rheumatoid arthritis reported improvement after five weeks of therapy; improvement has also been reported with lower doses. Diarrhea, rashes, and pruritus were the most common adverse effects. Auranofin is safe and effective for short- and long-term treatment of patients with rheumatoid arthritis. Its relative safety and potency compared with injectable gold salts and other drugs need further study.

UR - http://www.scopus.com/inward/record.url?scp=0021322557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021322557&partnerID=8YFLogxK

M3 - Review article

VL - 3

SP - 121

EP - 127

JO - Clinical Pharmacy

JF - Clinical Pharmacy

SN - 0278-2677

IS - 2

ER -